Provided by Tiger Trade Technology Pte. Ltd.

Adagene

4.02
-0.0700-1.71%
Post-market: 4.020.00000.00%19:30 EDT
Volume:61.31K
Turnover:246.91K
Market Cap:269.92M
PE:-10.65
High:4.12
Open:4.11
Low:3.97
Close:4.09
52wk High:4.85
52wk Low:1.30
Shares:67.14M
Float Shares:58.88M
Volume Ratio:0.15
T/O Rate:0.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3773
EPS(LYR):-0.3750
ROE:-28.50%
ROA:-13.95%
PB:3.02
PE(LYR):-10.72

Loading ...

Adagene Management Attends Morgan Stanley Global Healthcare Conference Fireside Chat

Reuters
·
Aug 20

Adagene to Participate in Three Upcoming Investor Conferences

GlobeNewswire
·
Aug 20

Adagene Director Cuong Do Reports Purchase of ADS Worth $7,500

Reuters
·
Aug 19

Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Natera (NTRA)

TIPRANKS
·
Aug 17

Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Mineralys Therapeutics, Inc. (MLYS) and Adagene (ADAG)

TIPRANKS
·
Aug 13

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 13

Adagene FY26 H1 Net Loss Widens to US$ 16.4 Million; Revenue Turns to US$ 1.6 Million

Reuters
·
Aug 12

Adagene H1 Adj. EPS $(0.20) Misses $(0.10) Estimate, Sales $1.620M

Benzinga Earnings
·
Aug 12

Press Release: Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates

Dow Jones
·
Aug 12

Adagene Inc. Expected to Post a Loss of 10 Cents a Share - Earnings Preview

Reuters
·
Aug 07

Adagene CEO Peter Luo Buys 23,245 ADS Worth $84,763.97

Reuters
·
Aug 07

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jul 14

Adagene Posts Investor Presentation Highlighting Adg126 Masked Anti-ctla-4 Program in MSS Colorectal Cancer

Reuters
·
Jul 07

Adagene joins Stifel Annual Virtual Oncology Event for fireside chat, investor meetings

Reuters
·
May 12

Adagene to Participate in Two Upcoming Investor Conferences

GlobeNewswire
·
May 12

Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT)

TIPRANKS
·
May 03

Analyst Initiates Buy on Muza Developer, Citing Promising MSS CRC Data, Clear Registrational Path, and Broader Expansion Upside Despite Cash Constraints

TIPRANKS
·
Apr 27

Adagene Showcases Promising Muzastotug Triplet Data at AACR 2026 for Liver and Colorectal Cancers

TIPRANKS
·
Apr 18

Adagene presents data from two Phase 1b/2 studies of muzastotug at AACR

TIPRANKS
·
Apr 18

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types

GlobeNewswire
·
Apr 18